Leqembi enters second consultation period following NICE draft guidance update

NICE convenes third committee meeting for additional appraisal consideration

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab).

Lecanemab was authorised by the MHRA for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) in adult patients who are apolipoprotein E ε4 heterozygotes or non-carriers on 22 August 2024.

NICE continues to assess the cost-effectiveness of lecanemab and the associated costs of administering it to patients based on…